Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol

The goal of this clinical trial is to evaluate an investigational ultralow dose Positron Emission Tomography (PET) imaging technique for Alzheimer's disease, mild cognitive impairment, other forms of dementia detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called Fluorine-18 (18F)-Florbetapir or 18F-Flutemetamol and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours

NCT Number	NCT07012993
Lead Sponsor	Akiva Mintz
Conditions	Alzheimer Disease, Mild Cognitive Impairment, Dementia, Healthy Volunteers
Enrollment	200 participants
Start Date	2025-05-20
Primary Completion	2030-06-30 (estimated)
Study Completion	2030-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-13